A $421M Bet That CGRP Isn't the Last Word on Migraines

MT-001 is a straightforward anti-PACAP antibody. It binds PACAP and stops it from doing its thing. The company plans to file for FDA clearance to start human testing (an IND application) around mid-2026, with Phase 2 proof-of-concept data expected by 2028.

MT-002 is the more ambitious swing: a bispecific antibody that targets both PACAP and CGRP simultaneously. Imagine combining the noise-canceling headphones with earplugs. The IND filing for this one is planned for early 2027, with initial Phase 1 safety data in healthy volunteers expected later that year.

Neither drug has been tested in a single human being yet. That's worth repeating. The $290 million financing is built on preclinical data and a biological hypothesis. The cash is designed to fund operations through 2028, which would cover those critical first readouts.

Why a Reverse Merger?

Mentari could have gone the traditional IPO route. But the biotech IPO window in 2026, while improving, still favors companies with actual clinical data. Only six biopharma IPOs priced in Q1 2026, raising $1.8 billion total. The bar is high.

A reverse merger offers a shortcut. InMed Pharmaceuticals is a small, publicly traded company on Nasdaq with a cannabinoid-focused pipeline that wasn't exactly lighting the world on fire. By merging with InMed, Mentari inherits the Nasdaq listing without the roadshow circus of a traditional IPO.

The math tells you who's really in charge here. Post-merger, Mentari's existing shareholders will own about 98.5% of the combined company. InMed shareholders get roughly 1.5%, plus contingent value rights tied to any future money from InMed's legacy assets. The combined entity will operate under the Mentari name with a new ticker symbol, governed by Mentari's board.

This isn't a merger of equals. It's a private company renting a public listing.

The Paragon Machine Keeps Printing

What makes this deal notable beyond the science is what it says about Paragon Therapeutics' model. The company operates like a biotech factory: discover antibodies in-house, form a new company around the best ones, pair it with capital from a tight network of investors (Fairmount shows up over and over), and launch.

Apogee Therapeutics, Paragon's first spinout, raised $169 million at launch in late 2022 and then pulled off a $345 million IPO by mid-2023. Oruka Therapeutics went public via its own reverse merger with ARCA biopharma in 2024. Now Mentari follows the same template.

The board composition tells the story of interconnection. Julie Bruno, a growth partner at Fairmount, will chair the board. Laura Sandler, COO of Oruka (another Paragon company), is part of this tight ecosystem, and the recurring cast of characters suggests a deliberate, repeatable strategy rather than a one-off.

What Could Go Wrong (and Right)

The bull case is straightforward. PACAP is biologically compelling, the migraine market is enormous, and CGRP drugs have proven that patients and payers will embrace injectable antibody preventives. If MT-001 or MT-002 shows strong efficacy in CGRP non-responders, Mentari could become an acquisition target for any large pharma company with migraine ambitions.

The bear case is equally clear. No human data exists yet. Anti-PACAP programs at other companies have had mixed results and complex safety profiles. Bispecific antibodies like MT-002 are notoriously tricky to manufacture and can trigger immune responses. And by the time these drugs could realistically reach the market (early 2030s at the earliest), the competitive landscape might look completely different.

There's also the question of whether a $421 million valuation is rich for a preclinical migraine company. That sits at the upper end for pre-proof-of-concept neurology biotechs. The investor syndicate clearly thinks the premium is justified; the market will have its own opinion once shares start trading.

The Bigger Picture

Mentari's deal is a snapshot of where biotech capital markets stand in mid-2026. The traditional IPO window is open, but only for companies with clinical validation. For everyone else, reverse mergers with large private placements have become the preferred alternative. It's a more controlled path: you negotiate the valuation, line up your investors in advance, and skip the volatility of a public bookbuild.

The migraine space, meanwhile, is entering its next chapter. CGRP was the prologue. What comes next (PACAP, TRPM8 inhibitors, digital therapeutics, implantable neuromodulation) will determine whether the hundreds of millions of people still suffering through migraines finally get real relief.

Mentari is betting $290 million that the answer involves blocking a protein most people have never heard of. In two years, we'll know if they were right.

Regeneron Just Bought a Ticket to Biotech's Hottest Party

Regeneron and Telix Pharmaceuticals just struck a deal worth up to $4.3 billion to co-develop radioligand cancer therapies. It's one of the largest radiopharma alliances ever, and it confirms that every major oncology player now wants nuclear-powered cancer drugs in their arsenal.